anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To easily obtain a liquid showing beautiful pearly gloss by mixing a dispersion liquid of fatty acid glycol ester to be used as crystal seeds and a solution of fatty acid glycol ester. CONSTITUTION:A dispersion liquid of pearly glossing agent having low concn. is prepared so that the liquid contains 0.1 - 5wt.% fatty acid glycol ester as crystal seeds. And a high-concn. pearly solution is prepared so that the soln. contains 15 - 65wt.% fatty acid glycol ester and 13 - 60wt.% surfactant. Both liquids are mixed and aged at such temp. lower than the melting point of the fatty acid glycol ester and that the high-concn. soln. does not solidify but uniformly grows, and under the average shearing rate of <=7sec<-1>. After the crystal seeds grow, the liquid is cooled under low shearing force. Thereby, a high-concn. dispersion liquid showing beautiful pearly gloss and having uniform crystal size and good dispersibility can easily and surely be obtained.
FIELD: chemistry of natural compounds. SUBSTANCE: method involves extraction of heart-shaped plume poppy (Macleya cordata) or microcarpous plume poppy (Macleya microcarpus) with hydrophobic solvent in the presence of alkaline agent. The end alkaloid bisulfates are precipitated by their conversion to bases and by repeated reprecipitation from hydrophobic organic solvent. Extraction is carried out with ethyl acetate or dichloroethane by successive treatment of some raw portions with a single volume of extractant by countercurrent principle. Ammonia aqueous solution is used as alkaline agent in the process of purification and chloroform is used as an extractant. By-side alkaloids are separated additionally by filtration and extraction of organic phase with water. EFFECT: simplified process, decreased consumption of raw and energy. 3 ex
PURPOSE:To provide a deodorant having a high deodorizing effect even on such sulfuric odor as emitted from methyl mercaptan, giving low tastiness and ensuring high safety by containing a diterpene derivative expressed by a plurality of specific formulae as an effective component in the deodorant. CONSTITUTION:A diterpene derivative expressed by formulae I, II and III is made to be contained in a deodorant as an effective component. In the formulae, R1, R2 and R5 are independently a hydrogen atom or a hydroxyl group, while R3 and R4 are independently a hydrogen atom, a hydroxyl group or an acetoxyl group. The deodorant so prepared is made to be contained in a composition for an oral cavity. In this case, the deodorant comes to contain a diterpene derivative existing in an extract from Isodon japonicus Hara as an effective component and, therefore, has a high deodorizing effect on such sulfuric odor as emitted from methyl mercaptan containing an odorous component. Also, the deodorant has low tastiness and ensures high safety for use. In addition, the deodorant can be used in such state as added to chewing gum, candy, and an oral composition such as toothpaste.
Subjects were randomly divided into two groups. Group A carried out a ten-minute Mirror Therapy exercise daily, for a total duration of six weeks. Group B acted as a control group for six weeks followed by six weeks of Mirror Therapy with the same characteristics as Group A. Upper extremity active range of motion, strength, dexterity, limb volume, right-left temperature difference, and health-related quality of life were evaluated before and after each period. Daily records on the visual analogue scale were used for pain evaluation. Effectiveness was calculated using mixed-effects modelling for between-group comparisons and within-group variability and identifying significant predictors.
Hydrocodone: Serious overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.

Acetaminophen: In acetaminophen overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma and coagulation defects may also occur.

Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

Treatment

A single or multiple drug overdose with hydrocodone and acetaminophen is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended.

Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.

For hydrocodone overdose, primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to narcotics, including hydrocodone. Since the duration of action of hydrocodone may exceed that of the antagonist, the patient should be kept under continued surveillance, and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.

Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.

Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.
Flushing is a typical physiological reaction to high emotional reactions. It is characterized by cutaneous vasodilation and a feeling of warmth and skin redness, especially in the face areas. Flushing is frequently linked to social anxiety, but it can also be a sign of a number of benign and malignant medical disorders. The study focuses on niacin-induced flushing, a well-researched side effect of the niacin, a drug which increases cholesterol levels. Niacin-induced flushing occurs when the hydroxycarboxylic acid receptor 2 (HCA2 or GPR109A) is activated. This starts a signaling cascade that releases prostaglandins, especially PGD2, which causes cutaneous vasodilation. Furthermore, niacin directly interacts with the transient receptor potential (TRP) channel TRPV1, offering a different, non-prostaglandin-based explanation for flushing brought on by niacin, highlighting the intricate physiological mechanisms behind this widespread occurrence. The review delves deeper into the advantages of niacin treatment for the cardiovascular system, highlighting how it can improve lipid profiles and lower cardiovascular events when used with statins. To sum it up, this study offers a thorough understanding of flushing, including its physiological foundation, many etiologies, diagnostic difficulties, and the subtleties of flushing caused by niacin. The investigation of innovative dose forms and nanomedicine highlights the continuous endeavors to improve patient compliance and reduce side effects, laying the groundwork for further developments in flushing treatment.
NK cell cytotoxicity is most powerful against acute myeloid leukemia (AML) cells, whereas their capacity to lyse ALL cells is generally low and difficult to predict. A novel method has been developed to redirect NK cells towards CD19, a molecule highly expressed on the surface of B-lineage ALL cells, but not expressed on normal cells other than B-lymphocytes. In this method, donor NK cells are first expanded by co-culture with irradiated K562 cell line modified to express membrane bound IL-15 and 41BB ligand (K562-mb15-41BBL). Overexpansion of these proteins promotes selective growth of NK cells. Then, the expanded NK cells are transduced with a signaling receptor that binds to CD19 (anti-CD19-BB-zeta). NK cells expressing these receptors showed powerful anti-leukemic activity against CD19+ ALL cells in vitro and in an animal model of leukemia.

This study represents the translation of laboratory findings into clinical application. It will allow us to assess the safety of infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL. In this same cohort, we also intend to study the in vivo lifespan and phenotype of genetically modified NK cells and explore the efficacy of NK cells in patients with B-lineage ALL.
This is a randomized, placebo-controlled, double-blind blind, repeated measures (cross-over) study. Approximately 12 healthy adult men will consume, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia.

Study participants will report to the Human Performance/Clinical Research Laboratory (HPCRL) on 6 separate occasions. On visit 1 study participants will undergo screening (e.g. medical history and 12-lead electrocardiogram and blood pressure at rest and during incremental exercise to volitional exhaustion), and will be instructed to avoid foods and drinks high in 5-HMF (e.g., coffee, malt, barley, dried fruits, and caramel) for at least 3 days before each subsequent visit. Visit 2 will comprise of a habituation visit during which subjects will be given the opportunity to rehearse the exercise test. Visits 3, 4, 5 and 6, will occur in a random order and be almost identical in nature. Study participants will abstain from vigorous physical exercise and alcohol consumption during the 24-hours prior to each visit. In addition, study participants will abstain from all food and beverages, except water, during the 4-hours prior to visits 3, 4, 5 and 6. On arrival subjects will be instrumented for measurement of heart rate, blood pressure and blood oxygen saturation. Following baseline determination subjects will consume either: a placebo, 1000 mg of Aes-103 or 3000 mg of Aes-103. 45 minutes after consumption, participants will enter our environmental chamber, adjusted randomly to either normoxia (21% oxygen) or hypoxia (15% oxygen). The pairing of normoxia/hypoxia and supplement will be as follows: placebo + normoxia, placebo + hypoxia, 1000 mg + hypoxia, and 3000 mg + hypoxia. Participants will remain seated in the environmental chamber for 15 minutes, after which they will complete a standardized warm-up bout of exercise (100 W for 30 minutes) followed by a brief time trial (time taken to cycle 12.5 km (\~7.75 miles)). Heart rate, blood pressure and blood oxygen saturation will be recorded every 5 minutes. During exercise, subjective ratings of perceived exertion (Borg Scale) will be recorded every 10 minutes, and at end-exercise.
The present invention concerns the methods and compositions related to pseudotyped viral vectors. Embodiments of the invention include pseudotyping expression cassettes that include nucleic acid elements for enhancing the titer of pseudotyped viral particles. Embodiments of the invention include novel methods and compositions related to making high titer pseudotyped retroviral vector compositions. A heterologous envelope glycoprotein is typically incorporated into the virus during the budding or virus production process. Certain embodiments of the invention include pseudotyped retroviral vectors comprising a heterologous envelope glycoprotein derived from a Jaagsiekte sheep retrovirus (JSRV env). Pseudotyped viruses or viral particles may have a modified host range that is influenced by the properties of the heterologous envelope glycoprotein. Thus, embodiments of the invention include improved methods and compositions related to pseudotyped viruses suitable for ex vivo and in vivo methods including gene transfer and other therapeutic and experimental methods.
PURPOSE: To efficiently deactivate viruses in a protein preparation product such as tissue thromboplastin for treating hemophilia, etc., by heating a solution of a preparation product of placenta protein, plasma protein, protein prepared with cell culture or any other microbial preparation, or the like, for a short period of time. CONSTITUTION: In this method, a heat exchanger module is formed by stacking up metal foils, which interposing a spacer between every adjacent two metal foils. At this time, the metal foils consist of metal cards so that each of the opposite surfaces of the metal cards is provided with two openings and the spacers consist of woven-fabric cards with openings consistent with those of metal cards so that these openings form two tubular passages at the time of stacking up the metal cards and woven-fabric cards. Heat exchangers W1.1 and W1.2, each of which is formed by filing a peripheral rim part of each of the woven-fabric cards and annular regions each surrounding a part of one of the openings of the woven-fabric card with a sealing agent, are placed so as to be a certain distance apart from each other by a spacer plate.  The temp. of each of the heat exchangers W1.1 and W1.2 is raised to a required heating temp. by passing hot water through them and thereafter, a solution of a preparation product of placenta protein, plasma protein, protein prepared with cell culture or any other microbial preparation, or the like, is supplied to the heat exchangers W1.1 and W1.2 through a pump P1 and heated at a >=65 deg.C heating temp. for a short period of time and to deactivate viruses in the preparation product.
Constitution differentiation is important for the prescription of Chinese medicines. In previous studies, researchers usually used constitutional questionnaires to determine constitutions.However, the importance of tongue diagnosis and pulse diagnosis remained unclear. The specific aim of this study is to evaluation indices of tongue diagnosis, auscultative diagnosis, and pulse diagnosis in the determination of constitutions. Meeting of specialists will determine the characteristics for each constitution first. This study plans to recruit 200 volunteers and determine their constitutions by constitutional questionnaires. Tongue manifestations and pulse pressure waveforms will be taken at the same time by standardized instruments. Relations between the indices and each constitution will be determined by multiple linear regression and logistic regression analysis. Then the percentage of importance of a specific index in a specific constitutional type could be determine.
Suicide is the third leading cause of death for American adolescents. Nearly one million adolescents a year attempt suicide and about 500,000 adolescents a year are admitted to psychiatric hospitals for suicide attempts or serious suicidal ideation. This leads to high emotional costs for families and financial cost for the health system. Yet, no medication, and less than 10 psychotherapy studies have focused on suicidal youth and findings are mixed. There has been a call for new and innovative approaches for depression treatment highlights the need for alternative interventions for suicidal youth as well. Attachment-Based Family Therapy (ABFT) offers a promising alternative to prior treatments. It is a manualized family therapy targeting processes associated with suicide and depression. ABFT seeks to improve the adolescent-caregiver relationship by increasing the family's capacity for discussing and negotiating affectively charged issues in the relationship. Improvements in the attachment relationship provide adolescents with improved capacity for affect regulation and the ability to use the caregiver as a source of protection and support. These strengths buffer adolescents against suicide and other risk behaviors. Four studies have demonstrated that ABFT can reduce suicidal ideation and depressive symptoms with an average effect size of .97. Unfortunately, interpretation of these studies is compromised by lack of a controlled comparison treatment. This study aims to test the efficacy of ABFT using a comparison group that controls for treatment dose, duration, therapist expertise, ecological factors, and family involvement. The study includes one year follow-up data, assessment staff blind to treatment condition and tests of the purported active ingredients of ABFT. Putative change processes will be tested including: a)adolescents' expectancies for parent availability, b) emotion regulation during parent-adolescent conflict discussions, and c) resolution of loss and abuse. To test this, Dr. Kobak, a leading adolescent attachment researcher, will use the Adult Attachment Interview and observational coding of the family interaction task to test these treatment mechanisms. If successful, the findings will provide evidence for both the efficacy and specificity of a family based treatment mechanism. The investigators will recruit and randomize 130 adolescents to 16 weeks of ABFT or Family-Enhanced Non-directive Supportive Therapy (FE-NST). Assessments will be conducted at baseline, 8, 16, 32 and 52 weeks. The primary and secondary aims assess whether ABFT reduces suicidal ideation, depression, family conflict, and future suicide attempts more effectively than control. Exploratory aims test a) whether ABFT can improve parent adolescent attachment, b) if attachment mediates outcome, and if a history of trauma, parental depression or family conflict moderate outcome. The study targets adolescents with severe and persistent suicidal ideation selected from inner city, minority youth.
The present invention relates to a co-crystal of Dedostat, which is a co-crystal of Dedostat with isoniazid, isonicotinyl, urea or nicotinamide. The invention also relates to salts of Dedostat, which are salts of Dedostat piperazine. The Dedosteine eutectic or salt has good stability and is beneficial to long-term storage of medicines. In addition, the water-absorbing agent has low hygroscopicity and good solubility, is favorable for being used as a medicine component, and has extremely high medicine development value. The invention also relates to a preparation method of the Dedosteine eutectic or salt. The preparation method provided by the invention is simple, has good repeatability and is suitable for industrial production.
African American adults with uncontrolled hypertension (HTN) will be assigned to complete an 11 week guided intervention using the FAITH! HTN app.
Patients with BRAF wild-type or BRAF mutant melanoma receive atezolizumab IV over 30-60 minutes and tiragolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
This is a randomized, double-blind, placebo-controlled, study in adult female subjects with mild to moderate hair loss. Following an up to 35-day screening period to determine eligibility, subjects will be randomly assigned into one of the following treatment arms: Nutrafol® vs. Placebo. Nutrafol® or Placebo will randomly assigned be administered daily to the subjects for 6 months starting on Day 2. The subjects will return to the study site at Day 90 and Day 180 for assessments. Additionally, the subjects will return to the study site approximately 48 hours after Day 0 (Baseline Visit) and D180 in order to assess hair growth rate. Nutrafol® or Placebo will be dispensed by the non-blinded study staff with nonlabeled containers containing the corresponding tablets. Efficacy ratings will be performed by a trained investigator who will not be aware of the subject's treatment randomization in order to preserve double-blinding of the study.
Participants assigned to Health and Wellness Education Training will receive 6-weeks of self-directed, online skills training on stress-reduction psychoeducation. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
PURPOSE: To obtain the stable human growth hormone aqueous preparation not requiring a lyophilization process, a careful dissolution operation on employment, etc., and capable of being stored as an aqueous solution and further injected as such. CONSTITUTION: The human growth hormone-containing aqueous medicine composition is prepared by dissolving the human growth hormone in a finely acidic or weakly acidic aqueous buffer solution. The aqueous solution is desirably the solution exhibiting the buffer effect in a pH range of 5-7, especially 5.5-6.5, and includes a citric acid buffer solution and a succinic acid buffer solution, especially the former buffer solution. The addition of sodium edetate to the aqueous solution enables to prevent the oxidation (the production of a sulfoxide) of the human growth hormone. The aqueous solution can sufficiently be used after stored at a cold place without requiring a lyophilization process. The storage is preferably performed at the cold place preferably at 2-8 deg.C.
This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
An application of theabrownin in preparing a medicament for treating liver cancer, which belongs to the technical field of theabrownin application. The method specifically comprises the following steps: the theabrownin can promote the apoptosis of hepatocellular carcinoma Huh7 cells by activating a JNK signal path and inhibit the growth of liver cancer transplantable tumors. The invention proves that the theabrownin has obvious antiproliferative and proapoptotic effects on Huh7 cells and has a dose-dependent effect through various experiments. Theabrownin promotes Huh7 cell apoptosis and inhibits growth of zebrafish liver cancer transplantable tumors by activating JNK signaling pathway. The inhibition rate of theabrownin on tumors can reach 48.1%. In addition, theabrownin regulates downstream apoptosis-related genes by activating P53 pathway PUMA, NOXA, Bax and Bcl-2 Etc. to promote apoptosis of P53 wild Sk-hep1 cells.